Back to Clinical Trials Overview

Back To Cancer Clinical Trials

Your search for "Non-Hodgkin's Lymphoma" returned 7 results:


A Phase III , Double Blind, Randomized, Placebo Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy and Immunogenicity of V212 in Recipients of Autologous Hematopoietic Cell Transplants (HCTs)
Principal Investigator(s): Luis M. Isola

Safety and Efficacy Study of CAL-101 in Patients with Previously Treated Low-grade Lymphoma
Principal Investigator(s): Joshua Brody

A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications
Principal Investigator(s): Luis M. Isola

A Phase II/III Randomized, Multicenter Trial Comparing Sirolimus plus Prednisone, and Sirolimus/Calcineurin Inhibitor plus Prednisone for the Treatment of Chronic Graft-versus-Host Disease
Principal Investigator(s): Eileen Scigliano

Phase 1b, Escalating Dose Study of AVL-292, a Bruton's Tyrosine Kinase (Btk) Inhibitor, as Monotherapy in Subjects with Relapsed and/or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
Principal Investigator(s): Janice L. Gabrilove

A Phase II Controlled Trial of a Single ProHema-CB unit (Ex Vivo CXCR4-Upregulated CD34+ Hematopoietic Progenitor Cells, Cord Blood) As Part of a Double Umbilical Cord Blood Transplant Following Myeloablative Conditioning For Patients Age 15-55 Years With Hematologic Malignancies
Principal Investigator(s): Luis M. Isola

Phase II Study of the Addition of Azacitidine (IND #87574, NSC #102816) to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older Patients with AML
Principal Investigator(s): Luis M. Isola